NCT00348673 - A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

HIV-1

Interventions

DRUG

UK-453,061

Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days

DRUG

UK-453,061

Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days

Trial Locations (3)

Pfizer Investigational Site, Hamburg

Pfizer Investigational Site, Cologne

Pfizer Investigational Site, Frankfurt am Main